Precigen, Inc. – NASDAQ:PGEN
Precigen stock price today
$3.1
+2.37
+326.82%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
Precigen stock price monthly change
-54.91%
month
Precigen stock price quarterly change
-54.91%
quarter
Precigen stock price yearly change
-48.14%
year
Precigen key metrics
Market Cap | 221.23M |
Enterprise value | 248.92M |
P/E | -2.81 |
EV/Sales | 4.66 |
EV/EBITDA | 5.44 |
Price/Sales | 3.78 |
Price/Book | 1.60 |
PEG ratio | -0.18 |
EPS | 0.04 |
Revenue | 20.78M |
EBITDA | -70.79M |
Income | 10.26M |
Revenue Q/Q | -42.46% |
Revenue Y/Y | -10.60% |
Profit margin | 53.01% |
Oper. margin | -131.7% |
Gross margin | 59.29% |
EBIT margin | -131.7% |
EBITDA margin | -340.64% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePrecigen stock price history
Precigen stock forecast
Precigen financial statements
| Jun 2023 | 1.76M | -20.31M | -1149.92% |
|---|---|---|---|
| Sep 2023 | 16.72M | 87.37M | 522.54% |
| Dec 2023 | 1.22M | -33.05M | -2691.86% |
| Mar 2024 | 1.06M | -23.73M | -2228.92% |
| Dec 2023 | 1.22M | -33.05M | -2691.86% |
|---|---|---|---|
| Mar 2024 | 1.06M | -23.73M | -2228.92% |
| Sep 2025 | 29.4M | -7.47M | -25.43% |
| Dec 2025 | 35.7M | -4.98M | -13.96% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 207527000 | 41.31M | 19.91% |
|---|---|---|---|
| Sep 2023 | 190688000 | 43.01M | 22.56% |
| Dec 2023 | 151043000 | 41.64M | 27.57% |
| Mar 2024 | 134847000 | 37.82M | 28.05% |
| Jun 2023 | -15.76M | 23.50M | -14.58M |
|---|---|---|---|
| Sep 2023 | -17.00M | 10.52M | -120K |
| Dec 2023 | -15.76M | 13.29M | -11K |
| Mar 2024 | -14.09M | 24.04M | 0 |
Precigen alternative data
| Sep 2023 | 209 |
|---|---|
| Oct 2023 | 209 |
| Nov 2023 | 209 |
| Dec 2023 | 209 |
| Jan 2024 | 209 |
| Feb 2024 | 209 |
| Mar 2024 | 202 |
| Apr 2024 | 202 |
| May 2024 | 202 |
| Jun 2024 | 202 |
| Jul 2024 | 202 |
Precigen other data
14.03%
-7.03%
of PGEN is owned by hedge funds
102
-55
28.11M
-14.15M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2023 | 11517712 | 0 |
| Aug 2023 | 1470345 | 359020 |
| Sep 2023 | 25000 | 0 |
| Dec 2023 | 96686 | 96686 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | THOMASIAN HARRY JR. officer: Chief Financial Officer | Common Stock | 135,714 | N/A | N/A | ||
Option | THOMASIAN HARRY JR. officer: Chief Financial Officer | Restricted Stock Units | 135,714 | N/A | N/A | ||
Option | PEREZ JEFFREY THOMAS officer: SVP, IP .. | Common Stock | 142,857 | N/A | N/A | ||
Option | PEREZ JEFFREY THOMAS officer: SVP, IP .. | Restricted Stock Units | 142,857 | N/A | N/A | ||
Option | SABZEVARI HELEN director, officer: President an.. | Common Stock | 1,071,429 | N/A | N/A | ||
Option | SABZEVARI HELEN director, officer: President an.. | Restricted Stock Units | 1,071,429 | N/A | N/A | ||
Option | SHAH RUTUL R officer: Chief Operating Officer | Common Stock | 117,142 | N/A | N/A | ||
Option | SHAH RUTUL R officer: Chief Operating Officer | Restricted Stock Units | 117,142 | N/A | N/A | ||
Option | LEHR DONALD P. officer: Chief Le.. | Common Stock | 164,285 | N/A | N/A | ||
Option | LEHR DONALD P. officer: Chief Le.. | Restricted Stock Units | 164,285 | N/A | N/A |
| Patent |
|---|
Application Filling date: 4 Feb 2022 Issue date: 19 May 2022 |
Application Filling date: 4 Feb 2022 Issue date: 19 May 2022 |
Grant Filling date: 4 Jun 2019 Issue date: 3 May 2022 |
Application Filling date: 8 Nov 2021 Issue date: 14 Apr 2022 |
Application Filling date: 13 Sep 2021 Issue date: 3 Mar 2022 |
Application Filling date: 11 Jun 2021 Issue date: 3 Mar 2022 |
Application Filling date: 31 Jul 2021 Issue date: 17 Feb 2022 |
Application Filling date: 27 Jun 2019 Issue date: 23 Dec 2021 |
Grant Utility: Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies Filling date: 11 May 2018 Issue date: 26 Oct 2021 |
Application Filling date: 5 May 2021 Issue date: 21 Oct 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2023 19 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 10 May 2023 | Q1 2023 Earnings Call Transcript |
| Q3 2022 9 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Helen Sabzevari MPH, Ph.D. (1962) Pres, Chief Executive Officer & Director | $1,770,000 |
| Mr. Donald P. Lehr (1975) Chief Legal Officer & Corporation Sec. | $808,210 |
| Mr. Jeffrey Thomas Perez (1972) Senior Vice President of Intellectual Property Affairs | $705,720 |
Precigen: August Is Pivotal For This Biotech Innovator
Precigen: RRP Targeting With AdenoVerse Technology Platform
Precigen's Express Lane: Racing Towards RRP Remedies (Rating Upgrade)
Strong Small-Cap Insider Buys: Q1 2023
Circling Back On Precigen
Precigen: A Substantially Undervalued And Differentiated Gene Therapy Company
MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile
-
What's the price of Precigen stock today?
One share of Precigen stock can currently be purchased for approximately $3.1.
-
When is Precigen's next earnings date?
Unfortunately, Precigen's (PGEN) next earnings date is currently unknown.
-
Does Precigen pay dividends?
No, Precigen does not pay dividends.
-
How much money does Precigen make?
Precigen has a market capitalization of 221.23M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 76.87% to 6.23M US dollars.
-
What is Precigen's stock symbol?
Precigen, Inc. is traded on the NASDAQ under the ticker symbol "PGEN".
-
What is Precigen's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Precigen?
Shares of Precigen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Precigen's key executives?
Precigen's management team includes the following people:
- Dr. Helen Sabzevari MPH, Ph.D. Pres, Chief Executive Officer & Director(age: 63, pay: $1,770,000)
- Mr. Donald P. Lehr Chief Legal Officer & Corporation Sec.(age: 50, pay: $808,210)
- Mr. Jeffrey Thomas Perez Senior Vice President of Intellectual Property Affairs(age: 53, pay: $705,720)
-
How many employees does Precigen have?
As Jul 2024, Precigen employs 202 workers.
-
When Precigen went public?
Precigen, Inc. is publicly traded company for more then 12 years since IPO on 8 Aug 2013.
-
What is Precigen's official website?
The official website for Precigen is precigen.com.
-
Where are Precigen's headquarters?
Precigen is headquartered at 20374 Seneca Meadows Parkway, Germantown, MD.
-
How can i contact Precigen?
Precigen's mailing address is 20374 Seneca Meadows Parkway, Germantown, MD and company can be reached via phone at +30 15569900.
Precigen company profile:
Precigen, Inc.
precigen.comExchange:
NASDAQ
Full time employees:
202
Industry:
Biotechnology
Sector:
Healthcare
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
20374 Seneca Meadows Parkway
Germantown, MD 20876
Germantown, MD 20876
CIK: 0001356090
ISIN: US74017N1054
CUSIP: 74017N105
